Exhibit 99.2

OraSure Technologies, Inc.

2020 First Quarter

Analyst-Investor Conference Call

May 6, 2020

Prepared Remarks of Dr. Stephen S. Tang and Roberto Cuca

Please see “Important Information” at the conclusion of the following prepared remarks

Introduction – Steve Tang

Thank you Jeanne.  Good evening everyone and welcome to our call.

Before we begin, on behalf of all of us at OraSure, I would like to express our sincere gratitude to the healthcare providers on the front lines fighting the COVID-19 pandemic. We would also like to acknowledge all those workers who are performing jobs that keep our country and society functioning. Your dedication, bravery and importance are vital to us. I also must thank all of our employees. Your outstanding efforts play an important role in helping people around the world. Our employees are being put to the test every day and they are responding with tenacity and excellence. I have never been prouder to lead our exceptional Company.

OraSure has a storied history of rising to the occasion of challenging health circumstances, having developed high quality diagnostic tests for HIV, HCV and Ebola. As you can imagine, we are doing everything we can to bring our expertise with infectious disease diagnostics and sample collection to the battle against COVID-19.  On the testing front, we are developing a pan-SARS-coronavirus rapid antigen in-home self-test that uses oral fluid samples, and an ELISA-based test for the detection of human anti-SARS-CoV-2 antibodies in oral fluid specimens.  Our molecular solutions business unit is working with laboratories and researchers to demonstrate the effectiveness of its sample collection technologies for coronavirus testing. Later in the call, I will update you on our progress on these items.  

Turning to the first quarter, I’m pleased to report that OraSure is off to a good start in 2020, with solid financial results.  The coronavirus pandemic is certainly affecting our business, and I will

discuss that in a minute.  But it is important to note that any negative impact from COVID-19 in Q1 was largely offset by additional product uptake in response to the pandemic.   As a result, the Company’s sales were in line with our own expectations from before the onset of the pandemic.

Because our Company is considered an essential business, we are permitted to continue operating in the various states and countries where our employees are located.  A large number of our employees can fulfill their job functions remotely and are working from home, in accordance with local stay-at-home requirements.  A key group of employees who must be on site are primarily manufacturing, warehouse, laboratory and R&D personnel.  We have implemented enhanced hygiene and social distancing protocols to ensure their safety.  Fortunately, we have had only one instance of COVID-19 infection reported among the more than 470 employees Company-wide.  That employee, who is field-based, is recovering well. For that, we are very grateful.

The COVID-19 pandemic is having a mixed impact on OraSure.  We saw some downward pressure from COVID-19 on revenues in our domestic professional HIV and HCV businesses and in our molecular sales to the academic market in Q1, as HIV and HCV testing programs and molecular research programs have been delayed or terminated because of COVID-19.   In our services business, revenues were also impacted as customers could not access samples housed at academic or medical facilities that were to be sent into our Microbiome services lab for processing. We see these trends continuing with a likely bigger impact on future quarters.   However, sales of our In-Home HIV test are rising as public health HIV testing programs in the U.S. are increasingly using our over-the-counter product as they adjust testing strategies in response to COVID-19. We are also seeing increased sales of our existing molecular saliva collection kits and oral swabs as some customers move from blood to saliva collection due to difficulties collecting blood samples under current circumstances.  

Assuming we are successful in our development and regulatory efforts, we anticipate that the new coronavirus testing products we are working on, and the expanded use of some existing molecular collection products, could make significant contributions later this year, especially as the need for COVID-19 testing increases.  

2

Our manufacturing operations have been unaffected by the pandemic and we have not had any significant disruptions from our suppliers.  Importantly, we expect that to continue.  With respect to logistics, we have seen additional challenges for international shipments, particularly by our Thailand contract supplier, largely due to a reduction in the availability of air freight, the closing of customs offices in certain countries and transport congestion.  We have generally been able to work around these issues by using more sea freight. Accordingly our shipping costs are and will continue to be a bit higher for certain destinations.  We are considering several options to expand current capacity to make sufficient quantities to support the growing demand for existing products as well as demand for COVID-19 products in development.  We will share more information about these options, once relevant and timely.

So despite the many moving parts and uncertainty surrounding the impact of COVID-19, we believe OraSure is well positioned to maintain its base business and to play an important role in fighting the pandemic.

Turning briefly to the highlights from Q1:

3

So, we are pleased with the way 2020 has started and we look forward to delivering a successful rest of the year despite the challenges that may arise from COVID-19.

With that, I will now turn things over to Roberto for a financial review of the quarter.  I will then share some additional thoughts on our business and take your questions.

First Quarter 2020 Financial Results – Roberto Cuca

Thanks Steve, and good evening everyone.

Our first quarter net revenues increased 5% to $31.6 million from the $30.1 million reported in the first quarter of 2019. Our net product and services revenues increased to $30.9 million or 9% compared to the prior-year period. Notably, the first quarter of 2019 included cryosurgical revenue of $2.6 million which did not recur in 2020 since we sold this line of business in August 2019.  Excluding these sales dollars from Q1 2019 revenues and the contributions of Diversigen, which we acquired in the fourth quarter of 2019, would result in an aggregate product and service revenue increase of 13% in the first quarter of 2020.

As Steve mentioned, international HIV sales increased 74% to $6.9 million from $4.0 million in the first quarter of 2019 due to higher sales of our HIV Self-Test into Africa.  Domestic HIV sales

4

decreased 2% to $4.2 million from $4.3 million in 2019 due to COVID-19 stay-at-home orders and the resulting deferral or shut-down of public health testing activities. This was offset by the launch of our In-Home HIV test into a new retail chain and the increased use of this OTC product in public health settings in reaction to COVID-19.

Domestic HCV sales decreased 18% in the first quarter of 2020 to $1.5 million from $1.8 million in the prior-year period, also largely due to the cessation of testing programs as a result of COVID-19, as well as the redirection of funding away from HCV testing to COVID testing.

International HCV sales in the first quarter of 2020 decreased 25% to $1.1 million from $1.5 million in the same period of 2019, primarily due to lower sales into Asia.  

Our total molecular revenues including other revenues increased 16% to $13.8 million in the first quarter compared to $11.9 million in 2019. Royalty income declined 59% to $446,000 in the first quarter of 2020, from $1.1 million in the same period of 2019. This reflects the continuing challenges faced in the consumer genomics ancestry market. Genomics product revenues increased 14% to $9.1 million in 2020 compared to $8.1 million in 2019 due to organic growth of existing customers and a shift from blood to saliva collection by customers using both sample types due to the inability to collect blood samples as a result of restrictions related to COVID-19. Microbiome product sales remained largely flat at $1.6 million in both the first quarters of 2020 and 2019. Lab service revenues generated by our subsidiaries, CoreBiome and Diversigen, increased 237% to $2.4 million in the first quarter of 2020 from $717,000 in the same period of 2019, largely due to the inclusion of revenues generated by Diversigen which was acquired in the fourth quarter of 2019.

Gross profit percentage for the first quarter of 2020 was 51% compared to 60% reported for the first quarter of 2019.  The decline is related to a revenue mix higher in sales of lower gross profit percentage products and services - including the addition of microbiome services acquisitions -and the absence of higher margin cryosurgical product sales, increased international freight costs, higher scrap and spoilage expense, and a decline in other revenues which contribute 100% to the gross profit percentage.

5

Our operating expenses for the first quarter of 2020 were $24.2 million compared to $21.9 million in the comparable period of 2019.  The increase in operating expense in the first quarter of 2020 was largely due to increased staffing costs, higher lab supply and consulting costs in support of bioinformatics and new product initiatives, increased legal fees and the inclusion of operating expenses incurred by Diversigen.  

We reported a net loss of $7.3 million, or $0.12 per share on a fully-diluted basis, for the first quarter of 2020, compared to a net loss of $3.3 million, or $0.05 per share, for Q1 2019. Results in these periods included acquisition-related charges of $1.1 million and $1.3 million respectively. Results in Q1 2019 also included $597,000 of transaction expenses. These charges amounted to approximately $0.02 and $0.03 in the first quarters of 2020 and 2019, respectively.

As Steve mentioned, we continue to maintain a solid cash and liquidity position.  Our cash and investments balance at March 31, 2020 was $176.2 million compared to $189.8 million at December 31, 2019. Cash generated by operating activities during the three months ended March 31, 2020 was $2.5 million compared to $528,000 million in the same period of 2019.

As Steve will describe in a bit more detail, the COVID-19 pandemic will likely not just exert downward pressure on certain existing lines of business, but will also present new opportunities for both existing products and services and for development efforts we are undertaking to address COVID-19 testing needs specifically.  The net effect of these future opportunities and challenges is difficult to predict reliably, and for this reason we are withdrawing financial guidance for 2020.  However, I do want to reiterate that this is because of the difficult-to-predict potential upside as well as downside presented by the pandemic.

With that, I will now turn the call back over to Steve for further business updates.

Infectious Disease Testing – Steve Tang

Thank you, Roberto. Turning now to Infectious Disease –

6

HIV and HCV Businesses

Our global HIV business continued to deliver a strong performance with revenues increasing 34% in the first quarter compared to Q1 2019.  The major driver was a 74% increase in international HIV revenues.  We shipped 2.0 million HIV Self-Tests to international markets in Q1, and this business rose 98% compared to the year-ago quarter as established countries continue to scale up testing and new countries begin to come on line.  Our domestic business was down 2% for the first quarter.

The COVID-19 pandemic is having its greatest impact on our domestic HIV business and global HCV business.  During the first quarter, most domestic HIV testing programs were either reduced or put on hold, which lowered demand for our professional products.  Because this started later in the quarter, our Q1 results were not significantly affected. In contrast, international HIV testing remained strong and we experienced only relatively minor issues resulting from COVID-19 related to shipping product overseas, which we were able to manage effectively.  If the COVID-19 pandemic begins to subside by the middle of the year, we believe there is a good chance that it will have little impact on our HIV Self-Test sales in future periods.  However, we expect the downward revenue pressure from COVID-19 to continue in the domestic HIV business.  How long this will last and the exact impact on revenues will depend on when the COVID-19 pandemic is resolved and the stay-at-home and social distancing restrictions are lifted.

Apart from COVID-19, we remain optimistic about HIV self-testing.  Population Services International has indicated it will extend the Self Testing Africa, or “STAR” initiative, to seven new countries (India, Indonesia, Uganda, Nigeria, Tanzania, Cameroon and Mozambique) under Phase III of that initiative.  We expect to receive orders under this Phase to begin in the second quarter with shipments occurring in the third and fourth quarters. The size of the program is expected to be similar to the 750,000 tests purchased under Phase I.  Not only will Phase III drive additional volume, it will also provide assistance for additional countries to start HIV self-testing programs on a national scale.  In this regard, the President’s Emergency Plan for AIDS Relief, or PEPFAR, which is a U.S. governmental initiative to address the global HIV/AIDS epidemic, has communicated guidance to its funded countries to consider increasing HIV self-testing during the COVID-19 pandemic as a way of continuing testing while maintaining social distancing.

7

The value of HIV self-testing in the face of COVID-19 is also being recognized domestically. Although sales of our professional HIV test are being negatively impacted, many public health departments are increasing purchases of our FDA approved in-home HIV test in order to enable their clients to continue HIV testing without having to come to a clinic.  In fact, the Centers for Disease Control and Prevention just last week issued a letter to all of their funded sites, encouraging them to use in-home self-testing for HIV in order to continue testing while complying with COVID-19 safety restrictions.  Since we have the only FDA approved in-home HIV test, we expect our revenues will be positively impacted, although it will likely not fully offset the downward pressure on our professional HIV franchise.  Of course, the ultimate impact will depend on when the COVID-19 situation begins to mitigate.

Turning briefly to HCV, revenues from this part of the business declined in Q1 compared to the prior year.  Many testing programs in the U.S. have been put on hold as both money and personnel are being shifted to COVID-related response activity.  Depending on when the COVID-19 situation is resolved, we would anticipate this business to eventually return to more normal levels of revenue. Our international business was not materially affected by COVID-19 in Q1, although it declined due to lower sales in Asia.

As previously mentioned, despite the challenges related to COVID-19, we see a number of upside opportunities, which could be substantial.

8

Molecular Solutions – Steve Tang

Turning to the Molecular Solutions Segment –

Revenues from our molecular business were up 25% compared to Q1 2019. Our commercial genomics business delivered a strong performance with some organic growth and increased purchases from a number of customers who historically used a combination of saliva and blood collection but are now shifting to a greater reliance on saliva, given the difficulties of obtaining blood samples in the COVID-19 environment.  We added 31 new commercial customers in Q1 and reported a 44% increase in the number of customers that are using both our genomics and microbiome products and in some cases services as well.  During Q1, we received a general use 510(k) clearance for our Oragene^®●Dx family of products.  This clearance strengthens our

9

regulatory and competitive position in the market and reduces the burden for test providers to adopt Oragene^®●Dx as an approved collector for their molecular assays.

Despite the strong first quarter results, as mentioned previously, sales to our academic customers were negatively impacted by COVID-19 as many of these customers delayed research activities not associated with COVID-19 testing.  This affected sales of our genomics, microbiome and urine collection kits to this market. We remain confident that both our genomics business in the disease risk management submarket and the microbiome market will return to double-digit annual growth after the pandemic.

As with the Infectious Disease Segment, we are also seeing a number of opportunities for increased business related to COVID-19. These could be significant and may more than offset any negative revenue impact on our Molecular Segment.  With the current issues with sample collection and overall testing capacity, the medical community is seeking alternatives to the accepted standard of collecting oropharyngeal and nasopharyngeal samples for COVID-19 testing.  Several publications have indicated that saliva, in addition to being quicker and more comfortable to collect for both patient and healthcare workers, is a technically superior sample type for the detection of COVID-19.  Our product lines, specifically Oragene^®●Dx, ORAcollect^®●RNA and OMNIgene^®●Oral, are well suited for this purpose.  Our proprietary stabilization chemistries are proven to be effective at stabilizing viral DNA and RNA.  Our Oragene^®●Dx line of products has been used by millions of consumers in both home and professional settings and is the only device of this type granted 510(k) clearance.  It is safe, non-toxic and easy to use, making it an ideal device for self-collection of samples for COVID-19 testing either at home or under supervision in a clinic.

We are working with several laboratories and diagnostic companies to validate our sample collection products for use with COVID-19 assays and feel confident that our devices will be compatible with at least some of the leading extraction techniques and testing platforms.  To date, we have engaged with over 150 customers from all over the world who all share the same goal – to broaden the scope of COVID-19 tests offered and provide an easy-to-use collection solution.  These customers span all types of test providers, including manufacturers of genetic tests, commercial labs and teaching hospitals.  To date, we have shipped kits for COVID validations to

10

over 60 customers and now have 10 purchase orders of significance in house expected to result in approximately $3.6 million in 2Q revenue, with more expected shortly.

As we announced on Monday, the first COVID-19 related Emergency Use Authorization, or “EUA,” incorporating one of our devices was issued last week by the FDA to Biocerna, LLC.  This EUA authorizes the use of our ORAcollect^®●RNA kit for the collection of anterior nasal samples for testing with the Biocerna COVID-19 assay.  We expect this to be the first of several EUAs incorporating our devices for COVID-19 testing using either nasal or saliva samples in professional and at-home settings.

In addition to the data we are generating with our customers, we have several ongoing studies of our own to confirm the safety and usability of our collection devices for COVID-19 testing.  These include studies to support at-home sample collection.  Preliminary data is encouraging and we look forward to using results from these studies to expand our regulatory clearances.

To meet the increased demand we are seeing for our products, we have been increasing capacity at our multiple suppliers.  We expect to be able to leverage multiple shifts to help increase our production capabilities.

Finally, in the lab services area, we have seen a consistent demand for lab services from our existing commercial customers with dedicated microbiome projects.  However, we anticipate a short-term weakening in the overall microbiome services market as major pharmaceutical companies re-focus efforts due to COVID-19.  As I noted previously, there have also been some delays in the academic market due to COVID-19 restrictions because of limited access to microbiome samples.

We are also continuing to integrate our microbiome laboratory businesses.  On May 8^th, the CoreBiome service operation will relocate to a new, state-of-the-art, 17,000 square foot facility in St. Paul, MN.  This facility has been designed to absorb the integration of both the legacy CoreBiome and Diversigen laboratory operations as well as part of our bioinformatics and software teams.  The lab is expected to be 100% operational for our CoreBiome customers on May 18^th.  The relocation of the Diversigen laboratory operations will begin in mid-May with a target date for completion near the end of Q3 2020.  Along with the physical integration, we will be

11

consolidating the branding for our microbiome services organizations under the Diversigen name.  We are in the final stretch for this rebranding work and within the next few weeks, all microbiome services will be operating under the Diversigen name with a new logo.

Organizational Changes – Steve Tang

A final topic I want to cover is the recent organizational changes we have announced.  

Tony Zezzo, who is the Business Unit Leader in charge of our Infectious Disease business, will be retiring this summer.  Tony has been with the Company for almost 10 years and has made significant contributions, including the global commercialization of our rapid HCV test and the substantial growth of our HIV franchise.  His dedication and steady leadership will certainly be missed and we wish him well in his retirement.  Tony’s successor will be Lisa Nibauer, who will join OraSure after serving for the past eight years with Becton Dickinson, most recently as the Vice President and General Manager of BD’s Medication Delivery Solutions business. Lisa has had extensive general management, sales and marketing responsibility, both at BD and at other large companies, and has exactly the skill set needed for this role.  I’m confident that she will be a strong leader for this important segment of our business.

We have also recently announced several Board changes.  Dr. David Shulkin, who was formerly Secretary of the U.S. Department of Veteran Affairs, joined our Board last month and is now serving on the Audit Committee and the Nominating and Corporate Governance Committee.  David has had a long and distinguished career in the medical and public health fields and has served at the highest levels within our Federal government.  His track record of strong executive leadership will enable him to be a significant contributor to our Board.  

We also announced the upcoming departure of two Board members.  Aradhana Sarin, who joined the Board in 2018 and currently serves as Chair of the Audit Committee and a member of the Nominating and Corporate Governance Committee, will be leaving the Board prior to our Annual Meeting so that she can devote more time to her duties as Chief Financial Officer of Alexion Pharmaceuticals. In addition, Chuck Patrick, who has been with the Board almost 14 years and serves as a member of the Audit Committee and member of the Nominating and Corporate

12

Governance Committee, will be retiring from the Board effective May 16th.  Both Aradhana and Chuck have been strong contributors to the Board and their advice and counsel will be missed.  We wish both of them much success for their future endeavors.

Conclusion – Steve Tang

In closing, 2020 is off to a good start with a solid Q1 performance, in spite of the pandemic.  Our HIV self-testing business is expected to continue to grow strongly and we are proud to leverage our expertise to help fight the COVID-19 pandemic.  We believe the opportunities for a new rapid oral fluid in-home coronavirus antigen test and a laboratory-based oral fluid antibody test, along with the expanded use of our molecular saliva collection products, are promising and could generate revenues well in excess of any revenues lost as a result of the COVID-19 pandemic.  Despite the uncertain current environment, our future is bright.  We are strong financially and we have the technical and management capabilities on board to enable us to successfully capture the opportunities before us.  At the same time, we continue to execute against our innovation growth strategy with the continued evaluation and pursuit of external acquisitions.  We look forward to reporting back on any significant new developments as they become available.

And with that, we will now take your questions.  Operator please proceed.

***

[Q &A session]

Final Conclusion – Steve Tang

Thank you for participating on today’s call and for your continued interest in OraSure. Have a good afternoon and evening. Stay safe and be well.

Important Information

This document contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results

13

to be materially different from those expressed or implied in these statements include, but are not limited to: ability to successfully manage and integrate acquisitions of other companies in a manner that complements or leverages our existing business, or otherwise expands or enhances our portfolio of products and our end-to-end service offerings, and the diversion of management’s attention from our ongoing business and regular business responsibilities to effect such integration; the expected economic benefits of acquisitions (and increased returns for our stockholders), including that the anticipated synergies, revenue enhancement strategies and other benefits from the acquisitions may not be fully realized or may take longer to realize than expected and our actual integration costs may exceed our estimates; impact of increased or different risks arising from the acquisition of companies located in foreign countries; ability to market and sell products, whether through our internal, direct sales force or third parties; impact of significant customer concentration in the genomics business; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the U.S. Food and Drug Administration (“FDA”) or other regulators; the impact of the novel coronavirus (“COVID-19”) pandemic on our business and our ability to successfully develop new products, validate the expanded use of existing collector products and commercialize such products for COVID-19 tests; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; ability to meet increased demand for the Company’s products; impact of replacing distributors; inventory levels at distributors and other customers; ability of the Company to achieve its financial and strategic objectives and continue to increase its revenues, including the ability to expand international sales; ability to identify, complete, integrate and realize the full benefits of future acquisitions; impact of competitors, competing products and technology changes; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid or urine testing, collection or other products; market acceptance and uptake

14

of microbiome informatics, microbial genetics technology and related analytics services; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention (“CDC”) or other agencies; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of our products; impact of contracting with the U.S. government; impact of negative economic conditions; ability to maintain sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of the Company’s stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; and general political, business and economic conditions. These and other factors that could affect our results are discussed more fully in our Securities and Exchange Commission (“SEC”) filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2019, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements.  The forward-looking statements are made as of the date of this call and we undertake no duty to update these statements.

15